Cargando…

Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials

We investigated the role of AS03(A) (here AS03), an α-tocopherol oil-in-water emulsion-based adjuvant system, on the long-term persistence of humoral and cell-mediated immune responses to A(H1N1)pdm09 influenza vaccines. In two studies, a total of 261 healthy adults (≤60 years old) were randomized t...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Most, Robbert G., Clément, Frédéric, Willekens, Julie, Dewé, Walthère, Walravens, Karl, Vaughn, David W., Leroux-Roels, Geert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461372/
https://www.ncbi.nlm.nih.gov/pubmed/28446441
http://dx.doi.org/10.1128/CVI.00553-16
_version_ 1783242329576964096
author van der Most, Robbert G.
Clément, Frédéric
Willekens, Julie
Dewé, Walthère
Walravens, Karl
Vaughn, David W.
Leroux-Roels, Geert
author_facet van der Most, Robbert G.
Clément, Frédéric
Willekens, Julie
Dewé, Walthère
Walravens, Karl
Vaughn, David W.
Leroux-Roels, Geert
author_sort van der Most, Robbert G.
collection PubMed
description We investigated the role of AS03(A) (here AS03), an α-tocopherol oil-in-water emulsion-based adjuvant system, on the long-term persistence of humoral and cell-mediated immune responses to A(H1N1)pdm09 influenza vaccines. In two studies, a total of 261 healthy adults (≤60 years old) were randomized to receive two doses of AS03-adjuvanted vaccine containing 3.75 μg of hemagglutinin (HA) or nonadjuvanted vaccine containing 15 μg of hemagglutinin (in study A) or 3.75 μg of hemagglutinin (in study B) 21 days apart. Hemagglutination inhibition (HI) antibody, memory B-cell, and CD4(+)/CD8(+) T-cell responses were characterized up to 1 year following dose 1. We also assessed the effects of age and seasonal influenza vaccination history. AS03-adjuvanted (3.75 μg HA) vaccine and nonadjuvanted vaccine at 15 μg but not at 3.75 μg HA elicited HI antibody responses persisting at levels that continued to meet European licensure criteria through month 12. At month 12, the geometric mean titer for AS03-adjuvanted vaccine was similar to that for nonadjuvanted (15-μg) vaccine in study A (1:86 and 1:88, respectively) and higher than that for nonadjuvanted (3.75-μg) vaccine in study B (1:77 and 1:35, respectively). A(H1N1)pdm09-specific CD4(+) T-cell and B-cell responses were stronger in AS03-adjuvanted groups and persisted only in these groups for 12 months at levels exceeding prevaccination frequencies. Advancing age and a seasonal vaccination history tended to reduce HI antibody and memory B-cell responses and, albeit less consistently, CD4(+) T-cell responses. Thus, AS03 seemed to enhance the persistence of humoral and cell-mediated responses to A(H1N1)pdm09 vaccine, allowing for antigen sparing and mitigating potential negative effects of age and previous seasonal vaccination. (These studies have been registered at ClinicalTrials.gov under registration no. NCT00968539 and NCT00989287.)
format Online
Article
Text
id pubmed-5461372
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-54613722017-06-27 Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials van der Most, Robbert G. Clément, Frédéric Willekens, Julie Dewé, Walthère Walravens, Karl Vaughn, David W. Leroux-Roels, Geert Clin Vaccine Immunol Clinical Immunology We investigated the role of AS03(A) (here AS03), an α-tocopherol oil-in-water emulsion-based adjuvant system, on the long-term persistence of humoral and cell-mediated immune responses to A(H1N1)pdm09 influenza vaccines. In two studies, a total of 261 healthy adults (≤60 years old) were randomized to receive two doses of AS03-adjuvanted vaccine containing 3.75 μg of hemagglutinin (HA) or nonadjuvanted vaccine containing 15 μg of hemagglutinin (in study A) or 3.75 μg of hemagglutinin (in study B) 21 days apart. Hemagglutination inhibition (HI) antibody, memory B-cell, and CD4(+)/CD8(+) T-cell responses were characterized up to 1 year following dose 1. We also assessed the effects of age and seasonal influenza vaccination history. AS03-adjuvanted (3.75 μg HA) vaccine and nonadjuvanted vaccine at 15 μg but not at 3.75 μg HA elicited HI antibody responses persisting at levels that continued to meet European licensure criteria through month 12. At month 12, the geometric mean titer for AS03-adjuvanted vaccine was similar to that for nonadjuvanted (15-μg) vaccine in study A (1:86 and 1:88, respectively) and higher than that for nonadjuvanted (3.75-μg) vaccine in study B (1:77 and 1:35, respectively). A(H1N1)pdm09-specific CD4(+) T-cell and B-cell responses were stronger in AS03-adjuvanted groups and persisted only in these groups for 12 months at levels exceeding prevaccination frequencies. Advancing age and a seasonal vaccination history tended to reduce HI antibody and memory B-cell responses and, albeit less consistently, CD4(+) T-cell responses. Thus, AS03 seemed to enhance the persistence of humoral and cell-mediated responses to A(H1N1)pdm09 vaccine, allowing for antigen sparing and mitigating potential negative effects of age and previous seasonal vaccination. (These studies have been registered at ClinicalTrials.gov under registration no. NCT00968539 and NCT00989287.) American Society for Microbiology 2017-06-05 /pmc/articles/PMC5461372/ /pubmed/28446441 http://dx.doi.org/10.1128/CVI.00553-16 Text en Copyright © 2017 van der Most et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/) .
spellingShingle Clinical Immunology
van der Most, Robbert G.
Clément, Frédéric
Willekens, Julie
Dewé, Walthère
Walravens, Karl
Vaughn, David W.
Leroux-Roels, Geert
Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials
title Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials
title_full Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials
title_fullStr Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials
title_full_unstemmed Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials
title_short Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials
title_sort long-term persistence of cell-mediated and humoral responses to a(h1n1)pdm09 influenza virus vaccines and the role of the as03 adjuvant system in adults during two randomized controlled trials
topic Clinical Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461372/
https://www.ncbi.nlm.nih.gov/pubmed/28446441
http://dx.doi.org/10.1128/CVI.00553-16
work_keys_str_mv AT vandermostrobbertg longtermpersistenceofcellmediatedandhumoralresponsestoah1n1pdm09influenzavirusvaccinesandtheroleoftheas03adjuvantsysteminadultsduringtworandomizedcontrolledtrials
AT clementfrederic longtermpersistenceofcellmediatedandhumoralresponsestoah1n1pdm09influenzavirusvaccinesandtheroleoftheas03adjuvantsysteminadultsduringtworandomizedcontrolledtrials
AT willekensjulie longtermpersistenceofcellmediatedandhumoralresponsestoah1n1pdm09influenzavirusvaccinesandtheroleoftheas03adjuvantsysteminadultsduringtworandomizedcontrolledtrials
AT dewewalthere longtermpersistenceofcellmediatedandhumoralresponsestoah1n1pdm09influenzavirusvaccinesandtheroleoftheas03adjuvantsysteminadultsduringtworandomizedcontrolledtrials
AT walravenskarl longtermpersistenceofcellmediatedandhumoralresponsestoah1n1pdm09influenzavirusvaccinesandtheroleoftheas03adjuvantsysteminadultsduringtworandomizedcontrolledtrials
AT vaughndavidw longtermpersistenceofcellmediatedandhumoralresponsestoah1n1pdm09influenzavirusvaccinesandtheroleoftheas03adjuvantsysteminadultsduringtworandomizedcontrolledtrials
AT lerouxroelsgeert longtermpersistenceofcellmediatedandhumoralresponsestoah1n1pdm09influenzavirusvaccinesandtheroleoftheas03adjuvantsysteminadultsduringtworandomizedcontrolledtrials